The Federal Medical and Biological Agency (FMBA) has completed the first stage of screening preclinical trials of its Mir-19 coronavirus vaccine, according to the website stopcoronavirus.rf
“The first stage of screening preclinical studies (specific immunogenicity, activation of humoral and T-cell immunity, primary safety) has been completed, as well as a study on the characterization of recombinant antigens regarding binding to natural receptors and virusneuralizing activity of antibodies induced by these antigens, created prototype vaccines based on recombinant proteins”, follows from the report.
Earlier, the head of the FMBA, Veronika Skvortsova, reported that preclinical trials of the FMBA coronavirus vaccine are planned to be completed in the first quarter of 2021, clinical trials will begin in July 2021, specifying that the first and second phases will be combined, because this is allowed by the vaccine trial protocol.
According to Skvortsova, the FMBA vaccine affects not the S protein, but other protein components of the virus and causes the development of immunity not through the activation of antibodies, but at the cellular level. According to the head of the FMBA, cellular immunity can last from 13 to 17 years.
